» Articles » PMID: 10836148

Human UDP-glucuronosyltransferases: Metabolism, Expression, and Disease

Overview
Publisher Annual Reviews
Specialties Pharmacology
Toxicology
Date 2000 Jun 3
PMID 10836148
Citations 347
Authors
Affiliations
Soon will be listed here.
Abstract

In vertebrates, the glucuronidation of small lipophilic agents is catalyzed by the endoplasmic reticulum UDP-glucuronosyltransferases (UGTs). This metabolic pathway leads to the formation of water-soluble metabolites originating from normal dietary processes, cellular catabolism, or exposure to drugs and xenobiotics. This classic detoxification process, which led to the discovery nearly 50 years ago of the cosubstrate UDP-glucuronic acid (19), is now known to be carried out by 15 human UGTs. Characterization of the individual gene products using cDNA expression experiments has led to the identification of over 350 individual compounds that serve as substrates for this superfamily of proteins. This data, coupled with the introduction of sophisticated RNA detection techniques designed to elucidate patterns of gene expression of the UGT superfamily in human liver and extrahepatic tissues of the gastrointestinal tract, has aided in understanding the contribution of glucuronidation toward epithelial first-pass metabolism. In addition, characterization of the UGT1A locus and genetic studies directed at understanding the role of bilirubin glucuronidation and the biochemical basis of the clinical symptoms found in unconjugated hyperbilirubinemia have uncovered the structural gene polymorphisms associated with Crigler-Najjar's and Gilbert's syndrome. The role of the UGTs in metabolism and different disease states in humans is the topic of this review.

Citing Articles

Insight into the structure, oligomerization, and the role in drug resistance of human UDP-glucuronosyltransferases.

Xue J, Li Q, Wang Y, Yin R, Zhang J Arch Toxicol. 2025; 99(3):1153-1165.

PMID: 39812829 DOI: 10.1007/s00204-024-03929-6.


Cryo-EM Structure of Recombinantly Expressed hUGDH Unveils a Hidden, Alternative Allosteric Inhibitor.

OBrien J, Kadirvelraj R, Tseng P, Ross-Kemppinen N, Crich D, Walsh Jr R Biochemistry. 2024; 64(1):92-104.

PMID: 39680853 PMC: 11713868. DOI: 10.1021/acs.biochem.4c00555.


Metabolism-involved drug interactions with traditional Chinese medicines in cardiovascular diseases.

Liang R, Hsu S, Chang T, Chiang T, Wang H, Ueng Y J Food Drug Anal. 2024; 30(3):331-356.

PMID: 39666289 PMC: 9635916. DOI: 10.38212/2224-6614.3421.


Phenol (bio)isosteres in drug design and development.

Dunker C, Schlegel K, Junker A Arch Pharm (Weinheim). 2024; 358(1):e2400700.

PMID: 39580699 PMC: 11726161. DOI: 10.1002/ardp.202400700.


Drug-drug interactions of plant alkaloids derived from herbal medicines on the phase II UGT enzymes: an introductory review.

Gunasaykaran S, Chear N, Ismail S, Mohammad N, Murugaiyah V, Ramanathan S Naunyn Schmiedebergs Arch Pharmacol. 2024; 398(2):1447-1464.

PMID: 39325152 DOI: 10.1007/s00210-024-03418-8.